Loss of IGFBP2 mediates alveolar type 2 cell senescence and promotes lung fibrosis

January 1, 2023
Cell Rep Med
https://pubmed.ncbi.nlm.nih.gov/36787736

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/36787736

Research summary

This study investigates the role of IGFBP2 in alveolar epithelial type 2 (AEC2) cell senescence and lung fibrosis. Loss of IGFBP2 leads to increased cellular senescence and fibrotic markers. Conversely, overexpression of human IGFBP2 in AEC2 cells reduces fibrosis in a bleomycin-induced lung injury model.

Key outcome of the study

IGFBP2 deficiency enhances AEC2 senescence and SASP production, exacerbating lung fibrosis. AEC2-specific restoration of IGFBP2 reduces fibrosis and inflammation, supporting its therapeutic relevance in pulmonary fibrosis.

Mouse model

Conditional Knockin mouse model developed by genOway, with human IGFBP2 cDNA inserted into the Rosa26 locus. Expression is driven by Sftpc-CreERT2 for AEC2-specific and tamoxifen-inducible activation.

TARGET:
Igfbp2
Insulin-like growth factor binding protein 2

Keywords

Pulmonary fibrosis, Alveolar epithelial cells, Senescence, IPF, AEC2-targeted therapy

Technical specifications

Conditional Knockin model, Rosa26 locus targeting, Sftpc-CreERT2 driver, Tamoxifen induction, Human IGFBP2 expression

Related products

Catalogue product

No items found.

Customized product

Reporter KI mouse

Use a reporter mouse Knockin for in vivo monitoring of transcriptional promoter activity, protein localization, cell trafficking, etc.

Quick KI mouse

The Rosa26 and Hprt gene loci are well suited for gene over-expression, reduced development time and cost with ready-to-use targeting vectors.